<DOC>
	<DOCNO>NCT00377728</DOCNO>
	<brief_summary>This study patient seasonal allergic rhinitis ( SAR ) compare effect versus placebo repeat dose intranasal GSK256066 use Vienna Challenge Chamber . GSK256066 potent highly selective phosphodiesterase-4 ( PDE4 ) inhibitor , currently development GSK treatment allergic rhinitis , asthma COPD . Subjects select basis display define moderate response pre-determined dose use . Opportunity assess efficacy compound versus placebo maximal trough plasma concentration . This study aim explore action repeat dos intranasal GSK256066 patient Seasonal Allergic Rhinitis Vienna Challenge Chamber compare placebo . 12-lead ECG , vital sign adverse event enquiry make throughout study . Nasal examination , symptom score ( TNSS ) , nasal lavage , nasal scrape allergen challenge assessment also perform various time point throughout study .</brief_summary>
	<brief_title>Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>Healthy subject define individual free clinically significant illness disease determine medical history Body mass index less 29.0 kg/mÂ² weight range 55.0kg ( female 50kg ) 95.0kg inclusive . History seasonal allergic rhinitis Exhibit moderate response 1500 grass pollen grains/m3 2h Vienna Challenge Chamber Positive skin prick test grass pollen within 12 month precede screen visit . Positive RAST grass pollen within 12 month precede screen visit . Current nonsmoker use tobacco product 6 month precede screen visit pack history le 10 pack year . Baseline FEV1 80 % predict baseline FEV1 ( maximum record value ) /FVC ( maximum record value ) 70 % predict No condition factor would make subject unlikely able stay chamber 6 hour . Capable give informed consent include compliance requirement restriction list consent form Available complete study measurement . Pregnant nursing female Women childbearing potential unwilling unable use appropriate method contraception outline least two week prior first dose study medication ; continue final pregnancy test perform On examination subject find structural nasal abnormality nasal polyposis , history frequent nosebleed , recent nasal surgery recent ongoing upper respiratory tract infection Responsible Physician 's opinion render subject unsuitable participation study Any respiratory disease mild stable asthma control occasional use asneeded shortacting betaagonists associate normal lung function . The subject likely unable abstain salbutamol use 8 hour challenge The subject history drug allergy , opinion physician responsible , contraindicate participation . The subject participate study new molecular entity previous 4 month clinical study previous 3 month The subject concurrently participate another clinical study subject expose investigational noninvestigational drug device . The subject screening QTc value &gt; 430msec ( &gt; 450msec female ) , PR interval outside range 120 240msec ECG suitable QT measurements The subject donate unit blood ( 450mL ) within previous 3 month intend donate within 3 month complete study . The subject currently take regular ( course ) medication whether prescribed , include steroid , vitamin , herbal remedy Paracetamol occasional need use shortacting beta agonist permit . Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease* , * subject require normal serum creatinine clearance value screen normal serum creatinine value 0.8 1.5 mg/dl The subject regularly , average , drink 4 unit alcohol per day The subject risk noncompliance study procedures/restrictions .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Seasonal Allergic Rhinitis Inflammation Vienna CHallenge Chamber</keyword>
</DOC>